Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chronic Myeloid Leukemia in Low- and Middle-Income Countries.

The New England journal of medicine·2026

Same author

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.

Leukemia·2026

Same author

Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.

The Lancet. Haematology·2026

Same author

Extended long-term follow-up and the survival of Stop Imatinib study.

Blood neoplasia·2026

Same author

Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.

Leukemia·2026

Same author

Development and Validation of a Simultaneous Quantification Method for 12 Targeted Therapies and 3 Active Metabolites in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry: An Application to Therapeutic Drug Monitoring in Patients With Hematological Malignancies.

Therapeutic drug monitoring·2025

Search research articles

Related Experiment Video

Updated: May 24, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Curing chronic myeloid leukemia.

Delphine Rea¹, Philippe Rousselot, Joelle Guilhot

¹Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, AP-HP, Paris, France. delphine.rea@sls.aphp.fr

Current Hematologic Malignancy Reports

|March 14, 2012

Summary

This summary is machine-generated.

Tyrosine kinase inhibitors (TKIs) control chronic myeloid leukemia (CML) but do not cure it. Targeting quiescent leukemic stem cells (LSCs) is crucial for a definitive cure in CML patients.

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: May 24, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Tyrosine kinase inhibitors (TKIs) have significantly improved survival for chronic myeloid leukemia (CML) patients.
Minimal residual disease prevents treatment cessation in most patients, transforming CML into a chronic condition.
Long-term TKI therapy raises concerns regarding safety, adherence, and healthcare costs.

Purpose of the Study:

To investigate the mechanisms underlying leukemic stem cell (LSC) behavior in TKI-treated CML patients.
To identify strategies for the complete eradication of LSCs to achieve a definitive cure for CML.

Main Methods:

The study focuses on understanding the biology of quiescent leukemic stem cells (LSCs).
Mechanistic insights into LSC survival under TKI treatment are explored.
Potential therapeutic strategies targeting LSCs are discussed.

Main Results:

TKIs are effective against the BCR-ABL1 oncoprotein but spare quiescent leukemic stem cells (LSCs).
The persistence of LSCs prevents a complete cure for chronic myeloid leukemia (CML).

Conclusions:

A definitive cure for CML requires targeting and eliminating quiescent leukemic stem cells (LSCs).
Further research into LSC biology is essential for developing curative strategies.